UVEAL MELANOMA

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests a drug called darovasertib in people with a rare eye cancer called uveal melanoma that hasn't spread. The goal is to see if the drug can prevent vision loss and save the eye from being removed. About 520 participants will be randomly assigned to receive the drug …

This study tests a new drug called belzupacap sarotalocan (AU-011) for people with a rare eye cancer (choroidal melanoma) or suspicious spots that could turn into cancer. The drug is activated by a laser to target and destroy cancer cells. About 100 participants will receive eith…

This study tests a drug called tebentafusp in people with a specific genetic type (HLA-A*0201) who have untreated metastatic uveal melanoma, a rare eye cancer that has spread. The trial uses a blood test to track tumor DNA and measure response. About 44 participants will receive …

This study tests whether the drug tebentafusp can prevent uveal melanoma from returning in patients at high risk after their initial treatment. About 290 participants will either receive the drug or be observed without treatment. The goal is to see if tebentafusp extends the time…

This early-stage trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for people with advanced uveal melanoma (an eye cancer) or certain sarcomas (soft tissue cancers). About 30 participants will have their tumor removed, immune…

This study tests whether combining two drugs, olaparib and pembrolizumab, can shrink tumors or slow the disease in people with advanced uveal melanoma, a rare eye cancer that has spread. About 37 adults with this condition will receive the combination treatment. The goal is to se…

This early-stage trial tests a new drug, NN3201, designed to attack cancer cells that have a specific marker called c-Kit. The study includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others. The main goal i…

This study looks at how the liver's immune system reacts when chemotherapy is given directly to the liver for eye melanoma that has spread there. Ten adults with this condition will have small liver tissue samples taken before and after treatment to measure immune cell changes. T…

This study looks at how choroidal melanoma and its treatment affect daily life and well-being. It involves 15 people already in a larger Phase 3 trial. Participants fill out questionnaires about their quality of life over two years. No new drugs or procedures are tested here.

This study looks for unknown genes that may cause uveal melanoma, a rare eye cancer. Only 20% of inherited cases have a known cause. Researchers will analyze DNA from 50 patients to find new gene changes linked to the disease. The goal is to improve screening and care for familie…

This study looks at how often a specific gene change (BAP1 mutation) is found in people with certain cancers like eye melanoma, skin melanoma, kidney cancer, and others. Researchers will study 500 patients and their family members to understand cancer patterns and risk factors. T…

This study follows 700 people with uveal melanoma (a rare eye cancer) who have a high chance of the cancer spreading to the liver. Researchers collect blood samples to look for biomarkers that might signal early spread. The goal is to see if personalized follow-up schedules can c…